Analysts Expect FibroGen Inc (FGEN) Will Announce Quarterly Sales of $47.10 Million
Wall Street analysts expect that FibroGen Inc (NASDAQ:FGEN) will post sales of $47.10 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for FibroGen’s earnings, with estimates ranging from $37.70 million to $52.70 million. FibroGen reported sales of $27.27 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 72.7%. The business is expected to issue its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that FibroGen will report full year sales of $185.07 million for the current financial year, with estimates ranging from $135.40 million to $256.80 million. For the next financial year, analysts expect that the company will report sales of $204.00 million per share, with estimates ranging from $92.00 million to $278.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for FibroGen.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.31. The firm had revenue of $43.95 million during the quarter, compared to analyst estimates of $28.70 million. FibroGen had a negative return on equity of 22.60% and a negative net margin of 85.59%.
In related news, Director Roberto Pedro Rosenkranz sold 1,000 shares of the company’s stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $63.65, for a total transaction of $63,650.00. Following the transaction, the director now directly owns 33,700 shares of the company’s stock, valued at approximately $2,145,005. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas B. Neff sold 18,900 shares of the company’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $56.75, for a total value of $1,072,575.00. Following the transaction, the chief executive officer now directly owns 2,761,894 shares in the company, valued at $156,737,484.50. The disclosure for this sale can be found here. Insiders have sold a total of 261,957 shares of company stock worth $16,373,387 over the last ninety days. 8.96% of the stock is currently owned by corporate insiders.
A number of large investors have recently made changes to their positions in FGEN. FMR LLC increased its position in FibroGen by 23.8% during the 2nd quarter. FMR LLC now owns 8,463,528 shares of the biopharmaceutical company’s stock valued at $529,817,000 after buying an additional 1,624,749 shares in the last quarter. PointState Capital LP acquired a new position in FibroGen during the 1st quarter valued at about $19,492,000. Emerald Advisers Inc. PA acquired a new position in FibroGen during the 2nd quarter valued at about $22,954,000. Emerald Mutual Fund Advisers Trust acquired a new position in FibroGen during the 2nd quarter valued at about $20,002,000. Finally, BlackRock Inc. increased its position in FibroGen by 4.6% during the 2nd quarter. BlackRock Inc. now owns 6,182,657 shares of the biopharmaceutical company’s stock valued at $387,037,000 after buying an additional 271,981 shares in the last quarter. 66.10% of the stock is currently owned by institutional investors.
FGEN opened at $59.75 on Monday. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.19. FibroGen has a 12 month low of $40.74 and a 12 month high of $68.55.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Read More: What Is An Exchange-Traded Fund (ETF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.